An observational study in Marfan Syndrome, Ehlers-Danlos Syndrome (EDS) and Mineral Density, sponsored by IRCCS Policlinico S. Donato. Recruiting at 1 site in Italy. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by IRCCS Policlinico S. Donato · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Marfan Syndrome with a site in Italy — 5 open to participants now, 6 under way, none of them phase 3. Marfan Syndrome · Italy.
Among the 11 studies in Marfan Syndrome with a site in Italy, this one is one of 2 that started in 2025, is one of 9 observational ones, and was the 10th registered.
61 studies on the registry are indexed under Marfan Syndrome; 15 are open to participants now.
Browse Marfan Syndrome studies →5 of the 11 studies in Marfan Syndrome with a site in Italy are open now. Recruiting first, the newest first:
IRCCS Policlinico S. Donato · Sites in Italy
Healthy volunteers
IRCCS Policlinico S. Donato · Sites in Italy
IRCCS Policlinico S. Donato · Sites in Italy
Ages 18+
IRCCS Policlinico S. Donato · Sites in Italy
Ages 18+ · Healthy volunteers
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 12 Marfan Syndrome studies recruiting now, 7 (58%) set no upper age limit and 4 (33%) stop at 75 or younger; 9 take children under 18; 1 takes healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is close to the median of 144 across 34 observational studies indexed under Marfan Syndrome.
Median enrollment 151 across the 2 interventional studies, 125 across the 9 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 11 has an industry lead sponsor. The 3 most frequent:
IRCCS Policlinico S. Donato is the lead sponsor of 105 studies on the registry; 53 are open to participants now.
IRCCS Policlinico S. Donato has 9 studies filed under Marfan Syndrome — fewer than ten, so there is no comparison to draw.
6 of the studies in Marfan Syndrome with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05700175IRCCS Policlinico S. DonatoTranscriptomic Study of Adult Population With Marfan Syndrome | 2026-12 |
| NCT06786754IRCCS Policlinico S. DonatoFibroblasts and Thoracic Aortic Aneurysms: in Vitro Characterization in With Marfan Syndrome and Genetic Aortic Diseases | 2026-12 |
| NCT05712577IRCCS Policlinico S. DonatoPsychological Support in Adult Patients With Marfan Syndrome | 2027-02-09 |
| NCT06782230IRCCS Policlinico S. DonatoScATtEred Rare Disease Biobanks: a Model of Sample/Data Collection With susTainablE and Shared Criteria | 2027-03-01 |
| NCT07169669IRCCS Policlinico S. DonatoMulticentre Longitudinal Study of Bone Mineralisation Characteristics in Marfan Syndrome and Ehlers-Danlos Syndrome | 2027-03-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 11 studies in Marfan Syndrome with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
General objective of this research is to evaluate the characteristics of bone mineralisation in patients with Marfan syndrome or Ehlers-Danlos syndrome on a large case series.
In particular aim is to obtain data regarding the characteristics of bone mineralisation, as well as their variation over time and the relationships existing with other clinical-anamnestic parameters, in patients with Marfan syndrome or Ehlers-Danlos syndrome by retrospectively analysing (data already collected for normal clinical practice and already available at the hospital) the case history of the Cardiovascular genetic center at IRCCS Policlinico San Donato and the related Computerized Bone Mineralometry (MOC) examinations performed at the Radiology Service of the same hospital between 1 September 2019 and 31 December 2022.
Marfan syndrome is a rare connective tissue disease with autosomal dominant transmission, characterised by altered production of the glycoprotein fibrillin-1 (FBN1), resulting from mutations in the gene encoding it.The complications most associated with the risk of mortality and morbidity are those affecting the cardiovascular system and those affecting the musculoskeletal system (spinal changes and chest deformities).
Ehlers-Danlos syndrome has an estimated prevalence of 1:5000 individuals and presents a pathological phenotype affecting the connective tissues that support the integumentary, skeletal, cardiovascular, and other organs and tissues. As in Marfan syndrome, marked alterations in the skeletal system (spine, thorax) and, in the vascular forms, a high risk of aneurysms and aortic and/or small and medium artery dissection, are found in those with Ehlers-Danlos syndrome.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Adult and paediatric subjects with Marfan syndrome referred to the Centre for Cardiovascular Genetic of IRCCS Policlinico San Donato
Adult and paediatric subjects with Ehlers Danlos Syndrome referred to the Centre for CardioVascular Genetics of IRCCS Policlinico San Donato and the Reference Centre for Ehlers-Danlos Syndromes Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico
Objective 1
To retrospectively evaluate the percentage of subjects with fractures in subjects with Marfan syndrome and Ehlers Danlos syndrome who performed at least one Bone Mineral Densitometry in the period between 1 September 2019 and 31 January 2025.
Time frame: Between 1 September 2019 and 31 January 2025.
Objective 2
Identifying patients with osteoporosis with T-score values below -2.5 SD and z-score values ≤ -2 SD in the paediatric population.
Time frame: Between 1 September 2019 and 31 January 2025.
Objective 3
Identify patients with osteopenia with T scores between -1 and -2.5 SD
Time frame: Between 1 September 2019 and 31 January 2025.
Objective 4
Identify adult patients with TBS values * TBS values ≤ 1200 (degraded micro-architecture); * TBS values between 1349 - 1201 (partially degraded micro-architecture).
Time frame: Between 1 September 2019 and 31 January 2025.
Started Oct 2025 (actual). Primary completion is estimated for Mar 2027, 17 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Mar 2026 → Mar 2027 and completion May 2026 → May 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.